NCT04858958 2025-11-19
FAVOUR
Allist Pharmaceuticals, Inc.
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT05466149 2025-11-19
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Allist Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT05994131 2025-04-30
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT02973763 2025-04-03
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04958967 2025-03-14
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
Allist Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT06339242 2024-04-01
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
Phase 2 Recruiting
NCT05209256 2022-01-26
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2/3 Unknown
NCT05165355 2022-01-18
ATHEM
Tongji University
Phase 2 Unknown